MeSH term
Frequency | Condition_Probility | Albumins/metabolism | 2 | 1.0 |
Antihypertensive Agents/*therapeutic use | 2 | 0.0 |
Humans | 970 | 0.0 |
Female | 375 | 0.0 |
Middle Aged | 254 | 0.0 |
Animals | 494 | 0.0 |
United States | 3 | 0.0 |
Carrier Proteins/genetics | 5 | 1.0 |
Eating | 8 | 5.0 |
*Energy Metabolism | 6 | 6.0 |
*Gene Expression | 6 | 0.0 |
Hypothalamus/chemistry/*metabolism | 2 | 100.0 |
*Intracellular Signaling Peptides and Proteins | 9 | 1.0 |
Mice | 83 | 0.0 |
Mice, Inbred BALB C | 6 | 0.0 |
Mice, Nude | 2 | 0.0 |
Neuropeptide Y/*genetics | 29 | 93.0 |
RNA, Messenger/analysis | 12 | 0.0 |
Research Support, Non-U.S. Gov't | 633 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 17 | 0.0 |
Tumor Cells, Cultured | 57 | 0.0 |
Weight Loss | 4 | 2.0 |
Adult | 268 | 0.0 |
Base Sequence | 48 | 0.0 |
Genetics, Population | 2 | 0.0 |
Genotype | 11 | 0.0 |
Korea | 2 | 0.0 |
Leucine/genetics | 2 | 3.0 |
Obesity/genetics | 6 | 11.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Proline/genetics | 2 | 3.0 |
Protein Sorting Signals/genetics | 2 | 2.0 |
Arcuate Nucleus/metabolism | 5 | 83.0 |
Binding, Competitive/drug effects | 4 | 6.0 |
Cell Line | 46 | 0.0 |
Chickens | 7 | 0.0 |
Cloning, Molecular | 43 | 0.0 |
In Situ Hybridization | 17 | 0.0 |
Ligands | 26 | 0.0 |
Molecular Sequence Data | 124 | 0.0 |
Naphthalenes/pharmacology | 6 | 7.0 |
Phylogeny | 9 | 0.0 |
Pyrrolidines/pharmacology | 2 | 4.0 |
RNA, Messenger/biosynthesis | 6 | 0.0 |
Sequence Homology, Amino Acid | 33 | 0.0 |
Transfection | 35 | 0.0 |
Amino Acid Sequence | 112 | 0.0 |
COS Cells | 8 | 0.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Neuropeptide Y/*metabolism | 64 | 91.0 |
Pancreatic Polypeptide/*metabolism | 4 | 36.0 |
Peptide YY/*metabolism | 4 | 57.0 |
RNA, Messenger/genetics/metabolism | 8 | 0.0 |
Receptors, Neuropeptide Y/genetics/*metabolism | 7 | 87.0 |
Recombinant Proteins/genetics/metabolism | 4 | 0.0 |
Tissue Distribution | 29 | 1.0 |
4-Butyrolactone/*analogs & derivatives/*pharmacology | 2 | 50.0 |
Adenosine Triphosphate/metabolism | 2 | 0.0 |
Energy Metabolism/*drug effects | 2 | 11.0 |
Enzyme Inhibitors/pharmacology | 9 | 0.0 |
Male | 461 | 0.0 |
Mice, Inbred C57BL | 8 | 0.0 |
Oxidation-Reduction | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 169 | 0.0 |
Analysis of Variance | 16 | 0.0 |
Calcitonin Gene-Related Peptide/biosynthesis | 2 | 40.0 |
Child | 40 | 0.0 |
Comparative Study | 141 | 0.0 |
Disease Progression | 3 | 0.0 |
Fluorescent Antibody Technique, Indirect | 15 | 1.0 |
Neurogenic Inflammation/physiopathology | 2 | 66.0 |
Neuropeptide Y/biosynthesis | 4 | 80.0 |
Neuropeptides/*biosynthesis | 3 | 50.0 |
Somatostatin/biosynthesis | 3 | 60.0 |
Statistics, Nonparametric | 5 | 0.0 |
Substance P/biosynthesis | 2 | 50.0 |
Vasoactive Intestinal Peptide/metabolism | 19 | 26.0 |
Cells, Cultured | 26 | 0.0 |
Follicle Stimulating Hormone/*blood | 2 | 2.0 |
Leptin/*pharmacology | 3 | 10.0 |
Neuropeptide Y/*pharmacology | 60 | 98.0 |
Nitric Oxide/metabolism | 2 | 1.0 |
Rats | 216 | 1.0 |
Rats, Inbred WKY | 4 | 5.0 |
Sequence Alignment | 18 | 0.0 |
Neuropeptide Y/*physiology | 32 | 94.0 |
Seizures/*physiopathology | 2 | 18.0 |
Acupuncture/*methods | 2 | 100.0 |
Blood Glucose/metabolism | 8 | 1.0 |
Immunohistochemistry | 121 | 0.0 |
Neurons/metabolism | 6 | 1.0 |
Neuropeptide Y/*biosynthesis | 10 | 90.0 |
Peptides/chemistry | 3 | 0.0 |
Rats, Sprague-Dawley | 55 | 2.0 |
Neuropeptides/metabolism | 10 | 18.0 |
Species Specificity | 32 | 1.0 |
In Vitro | 65 | 1.0 |
Nerve Fibers/metabolism | 6 | 28.0 |
Receptors, Neuropeptide Y/metabolism | 13 | 100.0 |
Swine | 53 | 3.0 |
Vasodilation | 2 | 5.0 |
Vasomotor System/*drug effects | 2 | 28.0 |
Body Composition | 6 | 2.0 |
Adolescent | 59 | 0.0 |
Leptin/*blood | 13 | 16.0 |
Neuropeptide Y/*blood | 81 | 97.0 |
Radioimmunoassay | 86 | 4.0 |
Aged | 176 | 0.0 |
Diagnosis, Differential | 4 | 0.0 |
Drugs, Chinese Herbal/*therapeutic use | 3 | 3.0 |
English Abstract | 41 | 0.0 |
*Phytotherapy | 2 | 2.0 |
Biological Markers | 14 | 0.0 |
Hypothalamus/cytology/*physiology | 2 | 66.0 |
Neurons/*metabolism | 12 | 4.0 |
Neuropeptide Y/metabolism/*physiology | 6 | 100.0 |
Proteins/metabolism | 4 | 0.0 |
Tumor Necrosis Factor-alpha/*metabolism | 2 | 0.0 |
Aged, 80 and over | 54 | 0.0 |
Vasoactive Intestinal Peptide/*metabolism | 3 | 4.0 |
Guinea Pigs | 40 | 4.0 |
Liver/*innervation | 3 | 100.0 |
Microscopy, Confocal | 3 | 0.0 |
Nitric-Oxide Synthase/*metabolism | 5 | 6.0 |
Mammals | 8 | 2.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
Administration, Oral | 7 | 0.0 |
Area Under Curve | 2 | 0.0 |
Blood Glucose/analysis | 5 | 0.0 |
Circadian Rhythm | 4 | 1.0 |
Depression, Chemical | 3 | 1.0 |
Hydrocortisone/blood | 6 | 1.0 |
Insulin/blood | 8 | 1.0 |
Insulin-Like Growth Factor I/analysis | 5 | 3.0 |
Testosterone/blood | 3 | 0.0 |
Calcitonin Gene-Related Peptide/physiology | 4 | 66.0 |
Interleukin-1/physiology | 2 | 2.0 |
Neuroimmunomodulation/physiology | 2 | 12.0 |
Neuropeptide Y/physiology | 19 | 79.0 |
Neuropeptides/*physiology | 14 | 34.0 |
Neurosecretory Systems/*physiopathology | 2 | 11.0 |
Serotonin/physiology | 4 | 13.0 |
Substance P/physiology | 5 | 35.0 |
Adenosine Triphosphate/pharmacology | 3 | 4.0 |
Adrenergic Fibers/*metabolism | 2 | 100.0 |
Biopsy | 10 | 0.0 |
Calcium/metabolism | 21 | 1.0 |
Drug Synergism | 7 | 0.0 |
Electric Stimulation | 23 | 10.0 |
Guanethidine/pharmacology | 3 | 100.0 |
Neuropeptide Y/*metabolism/pharmacology | 4 | 100.0 |
Norepinephrine/pharmacology | 17 | 22.0 |
Sympathomimetics/pharmacology | 2 | 14.0 |
Synaptic Transmission/drug effects/physiology | 4 | 30.0 |
Vasoconstriction/drug effects/physiology | 2 | 18.0 |
Calcitonin Gene-Related Peptide/*blood | 3 | 60.0 |
Cerebrovascular Circulation | 2 | 3.0 |
Liver Cirrhosis/blood | 2 | 4.0 |
Vasoactive Intestinal Peptide/*blood | 4 | 5.0 |
CHO Cells | 28 | 1.0 |
Hamsters | 38 | 0.0 |
Receptors, Neuropeptide Y/chemistry/*metabolism | 2 | 100.0 |
Structure-Activity Relationship | 39 | 1.0 |
Calcitonin Gene-Related Peptide/metabolism | 11 | 29.0 |
Carrier Proteins/metabolism | 7 | 0.0 |
*Membrane Transport Proteins | 5 | 0.0 |
NADPH Dehydrogenase/metabolism | 2 | 8.0 |
Neuropeptide Y/metabolism | 42 | 67.0 |
Substance P/metabolism | 11 | 20.0 |
Tyrosine 3-Monooxygenase/metabolism | 12 | 7.0 |
*Vesicular Transport Proteins | 4 | 2.0 |
Creatinine/blood | 3 | 0.0 |
Norepinephrine/blood | 26 | 13.0 |
Renal Circulation/physiology | 2 | 15.0 |
Vasoconstriction/physiology | 4 | 30.0 |
Adenylate Cyclase Toxin | 2 | 8.0 |
Chromones/pharmacology | 2 | 0.0 |
Cyclic AMP/metabolism | 22 | 4.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
Indoles/pharmacology | 2 | 0.0 |
Maleimides/pharmacology | 2 | 2.0 |
Morpholines/pharmacology | 2 | 0.0 |
Pancreatic Polypeptide/*pharmacology | 3 | 42.0 |
Pertussis Toxin | 7 | 4.0 |
Receptors, Neuropeptide Y/*classification/*metabolism | 2 | 100.0 |
Virulence Factors, Bordetella/pharmacology | 7 | 3.0 |
Brain/*metabolism | 23 | 5.0 |
Arcuate Nucleus/physiology | 2 | 66.0 |
Autonomic Nervous System/drug effects/*physiology | 2 | 50.0 |
Hypothalamus/drug effects/*physiology | 3 | 42.0 |
Neurons/drug effects/physiology | 2 | 9.0 |
Brain/*physiology | 6 | 5.0 |
Energy Metabolism | 6 | 3.0 |
Homeostasis | 7 | 1.0 |
Neurons/*physiology | 5 | 3.0 |
Signal Transduction | 19 | 0.0 |
Adipose Tissue/physiology | 2 | 9.0 |
Feedback | 7 | 3.0 |
*Homeostasis | 3 | 5.0 |
Proteins/*physiology | 5 | 2.0 |
Calcitonin Gene-Related Peptide/analysis | 37 | 52.0 |
Image Processing, Computer-Assisted | 7 | 1.0 |
Neuropeptide Y/analysis | 55 | 78.0 |
Substance P/analysis | 46 | 49.0 |
Tyrosine 3-Monooxygenase/analysis | 21 | 25.0 |
Vasoactive Intestinal Peptide/analysis | 51 | 51.0 |
Conserved Sequence | 4 | 0.0 |
Evolution, Molecular | 3 | 0.0 |
Gene Duplication | 2 | 1.0 |
Dose-Response Relationship, Drug | 53 | 0.0 |
Hemodynamic Processes/drug effects | 3 | 1.0 |
Injections, Intra-Arterial | 3 | 7.0 |
Injections, Intraventricular | 21 | 15.0 |
Microinjections | 7 | 3.0 |
Anthropometry | 2 | 0.0 |
Body Mass Index | 20 | 1.0 |
Insulin/*blood | 5 | 2.0 |
Recurrence | 5 | 0.0 |
Weight Gain | 3 | 4.0 |
Alzheimer Disease/*cerebrospinal fluid | 2 | 11.0 |
Case-Control Studies | 20 | 0.0 |
Dementia/*cerebrospinal fluid | 3 | 27.0 |
Neuropeptide Y/*cerebrospinal fluid | 11 | 100.0 |
Somatostatin/*cerebrospinal fluid | 4 | 66.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 0.0 |
Hypertension/*blood | 4 | 6.0 |
Pregnancy | 19 | 0.0 |
Atrial Natriuretic Factor/blood | 7 | 8.0 |
Infusions, Intravenous | 6 | 0.0 |
Appetite/*physiology | 6 | 46.0 |
Corticotropin-Releasing Hormone/*physiology | 3 | 33.0 |
Drug Interactions | 10 | 0.0 |
Leptin/*physiology | 4 | 36.0 |
Obesity/*metabolism | 3 | 4.0 |
Blotting, Western | 7 | 0.0 |
Cyclic AMP/biosynthesis | 5 | 4.0 |
Forskolin/pharmacology | 18 | 4.0 |
Prostatic Neoplasms/*pathology | 3 | 2.0 |
Receptors, Neuropeptide Y/analysis/*biosynthesis | 2 | 100.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Stress, Mechanical | 2 | 0.0 |
Binding Sites | 35 | 0.0 |
Cell Differentiation | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 4 | 0.0 |
Gene Expression Regulation | 6 | 0.0 |
Neuroblastoma/*metabolism/pathology | 2 | 5.0 |
Nuclear Proteins/genetics/*metabolism | 2 | 0.0 |
Transcription Factors/genetics/*metabolism | 3 | 0.0 |
Appetite/drug effects/physiology | 4 | 66.0 |
Brain/physiology | 3 | 4.0 |
Clinical Trials | 6 | 0.0 |
Hunger/physiology | 3 | 33.0 |
Animals, Newborn | 2 | 0.0 |
Disease Models, Animal | 14 | 0.0 |
*Maternal Deprivation | 2 | 40.0 |
Sex Factors | 4 | 0.0 |
Binding, Competitive | 34 | 1.0 |
Cross-Linking Reagents | 3 | 0.0 |
Drug Stability | 2 | 0.0 |
Injections, Intravenous | 9 | 1.0 |
Metabolic Clearance Rate | 3 | 0.0 |
Antibody Specificity | 3 | 0.0 |
Calcium-Binding Protein, Vitamin D-Dependent/analysis/immunology | 2 | 50.0 |
Neuropeptide Y/*analysis | 43 | 97.0 |
Nitric-Oxide Synthase/*analysis | 4 | 26.0 |
Parvalbumins/analysis/immunology | 2 | 50.0 |
Somatostatin/*analysis | 5 | 27.0 |
Protein Conformation | 12 | 0.0 |
Aging/physiology | 2 | 1.0 |
Gene Frequency | 6 | 0.0 |
*Polymorphism, Genetic | 10 | 0.0 |
Reference Values | 35 | 0.0 |
Antigens, CD26/*metabolism | 2 | 9.0 |
Kinetics | 37 | 0.0 |
Neuropeptides/*metabolism | 26 | 30.0 |
Spectrum Analysis, Mass | 3 | 0.0 |
Substrate Specificity | 6 | 0.0 |
Calcitonin Gene-Related Peptide/pharmacology | 3 | 10.0 |
Cytotoxicity, Immunologic/drug effects | 2 | 1.0 |
Neuropeptide Y/pharmacology | 20 | 86.0 |
Somatostatin/pharmacology | 5 | 10.0 |
Substance P/pharmacology | 7 | 21.0 |
Vasoactive Intestinal Peptide/pharmacology | 11 | 13.0 |
Galanin/*blood | 5 | 55.0 |
Receptor, Melanocortin, Type 4 | 2 | 2.0 |
Receptors, Corticotropin/physiology | 3 | 37.0 |
Angina Pectoris/*blood | 2 | 9.0 |
Sympathetic Nervous System/*physiopathology | 4 | 10.0 |
Body Weight | 8 | 1.0 |
Corticotropin-Releasing Hormone/analysis/*metabolism | 2 | 66.0 |
DNA Primers | 6 | 0.0 |
Histocytochemistry | 20 | 3.0 |
Hypothalamus/*metabolism | 7 | 22.0 |
Neuropeptide Y/analysis/*metabolism | 3 | 100.0 |
Time Factors | 33 | 0.0 |
Nerve Fibers/*metabolism | 5 | 31.0 |
Thiolester Hydrolases/metabolism | 4 | 23.0 |
Ubiquitin Thiolesterase | 26 | 25.0 |
Hypothalamus/metabolism | 16 | 33.0 |
Protein Isoforms | 2 | 0.0 |
*Receptors, Cell Surface | 7 | 1.0 |
Leptin/*metabolism | 4 | 22.0 |
Peptide Fragments/*metabolism | 2 | 1.0 |
Eating/*drug effects | 5 | 25.0 |
Models, Animal | 4 | 1.0 |
Rats, Long-Evans | 2 | 4.0 |
Receptors, Neuropeptide Y/*agonists/metabolism | 4 | 100.0 |
Arginine/administration & dosage/*analogs & derivatives/pharmacology | 2 | 100.0 |
Eating/drug effects/physiology | 3 | 75.0 |
Feeding Behavior/*drug effects/physiology | 4 | 66.0 |
Neuropeptides/administration & dosage/*pharmacology | 2 | 66.0 |
Peptide Fragments/administration & dosage/pharmacology | 2 | 50.0 |
Receptors, Neuropeptide Y/antagonists & inhibitors | 4 | 80.0 |
Signal Transduction/drug effects | 4 | 0.0 |
Neuropeptide Y/genetics | 9 | 90.0 |
Neuropeptides/*genetics | 4 | 8.0 |
Comorbidity | 3 | 1.0 |
Primary Prevention | 2 | 16.0 |
Risk Factors | 8 | 0.0 |
Autoradiography | 15 | 2.0 |
Cell Count | 3 | 0.0 |
Child, Preschool | 33 | 0.0 |
Drug Resistance | 4 | 0.0 |
*Neuronal Plasticity | 2 | 10.0 |
Neuropeptide Y/genetics/*metabolism | 6 | 85.0 |
RNA, Messenger/metabolism | 18 | 0.0 |
Radioligand Assay | 16 | 3.0 |
Receptors, Neuropeptide Y/*metabolism | 18 | 81.0 |
Peptides/*metabolism | 13 | 6.0 |
Japan | 2 | 0.0 |
Leucine/*genetics | 4 | 16.0 |
Neuropeptide Y/blood/*genetics | 2 | 100.0 |
Polymerase Chain Reaction | 24 | 0.0 |
Proline/*genetics | 4 | 20.0 |
Protein Sorting Signals/*genetics | 3 | 8.0 |
Cholecystokinin/physiology | 4 | 33.0 |
Cross-Sectional Studies | 2 | 0.0 |
Dopamine/physiology | 2 | 3.0 |
Eating/drug effects/*physiology | 4 | 50.0 |
Leptin/physiology | 4 | 33.0 |
Nerve Tissue Proteins/physiology | 3 | 7.0 |
Nicotine/*pharmacology | 4 | 15.0 |
Prospective Studies | 12 | 0.0 |
Proteins/physiology | 4 | 2.0 |
Receptors, Neuropeptide Y/drug effects/physiology | 2 | 100.0 |
Cholesterol/blood | 3 | 0.0 |
Exons | 4 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
Sequence Analysis, DNA | 6 | 0.0 |
Receptors, Neuropeptide/*metabolism | 2 | 18.0 |
Activins | 2 | 2.0 |
Cyclic AMP/pharmacology | 2 | 1.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
Gonadorelin/pharmacology | 3 | 6.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Neuropeptides/pharmacology | 5 | 16.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Infant | 30 | 0.0 |
Infant, Newborn | 23 | 0.0 |
Neurons/*enzymology | 2 | 2.0 |
Brain/metabolism | 8 | 1.0 |
Calcium Channels/metabolism | 2 | 6.0 |
Inhibitory Concentration 50 | 3 | 1.0 |
Kidney/metabolism | 3 | 0.0 |
Kidney Cortex/metabolism | 2 | 13.0 |
Protein Binding | 13 | 0.0 |
Rabbits | 25 | 0.0 |
Receptors, Neuropeptide Y/*antagonists & inhibitors | 11 | 84.0 |
*Signal Transduction | 2 | 0.0 |
Sodium/*metabolism | 3 | 4.0 |
Cell Division/drug effects | 3 | 0.0 |
Tumor Cells, Cultured/drug effects | 4 | 0.0 |
Blood Pressure/drug effects | 15 | 2.0 |
Cross-Over Studies | 5 | 0.0 |
Heart Rate/drug effects | 10 | 4.0 |
Gene Expression/physiology | 3 | 0.0 |
Receptors, Neuropeptide Y/*genetics | 6 | 54.0 |
*Suicide | 2 | 11.0 |
Hormones/blood | 2 | 1.0 |
Neuropeptide Y/blood | 21 | 91.0 |
Neuropeptides/*blood | 12 | 66.0 |
Neurotransmitters/*blood | 2 | 25.0 |
Catecholamines/*blood | 4 | 12.0 |
Half-Life | 2 | 0.0 |
Pheochromocytoma/*blood/surgery | 2 | 66.0 |
Circular Dichroism | 10 | 2.0 |
Peptide Biosynthesis | 5 | 10.0 |
Eating/drug effects | 10 | 26.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 33 | 0.0 |
Aging | 5 | 1.0 |
Arginine/*analogs & derivatives/pharmacology | 8 | 50.0 |
Energy Intake/drug effects | 2 | 33.0 |
Mice, Knockout | 11 | 0.0 |
Mice, Transgenic | 5 | 0.0 |
Neuropeptide Y/genetics/*physiology | 3 | 100.0 |
Phenotype | 7 | 0.0 |
Feeding Behavior/*physiology | 9 | 31.0 |
Cyclosporine/therapeutic use | 2 | 2.0 |
Drug Therapy, Combination | 2 | 0.0 |
Follow-Up Studies | 6 | 0.0 |
Corticotropin/*blood | 2 | 3.0 |
Eating/*physiology | 7 | 10.0 |
Hydrocortisone/*blood | 3 | 2.0 |
Leptin/blood | 5 | 9.0 |
Hypothalamus/*physiology | 6 | 21.0 |
Leptin/metabolism | 3 | 17.0 |
*Receptors, G-Protein-Coupled | 3 | 1.0 |
Somatostatin/secretion | 2 | 18.0 |
Biological Markers/blood | 2 | 0.0 |
Data Interpretation, Statistical | 2 | 0.0 |
Vasoactive Intestinal Peptide/blood | 3 | 7.0 |
Hippocampus/metabolism | 6 | 6.0 |
Pancreatic Polypeptide/metabolism | 8 | 38.0 |
Receptors, Neuropeptide Y/*physiology | 11 | 91.0 |
Arcuate Nucleus/*metabolism | 7 | 63.0 |
Cell Movement | 2 | 0.0 |
Endothelium, Vascular/*cytology/metabolism | 2 | 3.0 |
Immunoblotting | 3 | 0.0 |
Neuropeptide Y/*metabolism/physiology | 2 | 100.0 |
Umbilical Cord/metabolism | 3 | 33.0 |
Blotting, Northern | 11 | 0.0 |
Bradykinin/pharmacology | 3 | 6.0 |
Estrenes/pharmacology | 3 | 7.0 |
GTP-Binding Proteins/metabolism | 3 | 1.0 |
Glioblastoma/*metabolism | 2 | 6.0 |
Phosphodiesterase Inhibitors/pharmacology | 2 | 1.0 |
Pyrrolidinones/pharmacology | 3 | 5.0 |
Receptors, Neuropeptide Y/*chemistry/*metabolism | 2 | 100.0 |
Pancreatic Polypeptide/*chemistry/*metabolism | 2 | 100.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
Macaca mulatta | 9 | 2.0 |
Amino Acids/chemistry | 2 | 1.0 |
Brain/*metabolism/pathology | 3 | 3.0 |
Chromatography, High Pressure Liquid | 37 | 2.0 |
Open Reading Frames | 2 | 0.0 |
Fetus/cytology | 2 | 3.0 |
Gene Expression/drug effects | 4 | 0.0 |
Interleukin-1/*pharmacology | 2 | 0.0 |
Neuropeptide Y/analysis/*genetics | 3 | 100.0 |
Gene Expression Regulation/drug effects | 4 | 0.0 |
Neuropeptides/genetics/*metabolism | 2 | 8.0 |
Stimulation, Chemical | 6 | 1.0 |
Peptide YY/chemistry/*metabolism | 2 | 100.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 2 | 0.0 |
DNA/biosynthesis | 7 | 1.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Retina/*cytology | 2 | 18.0 |
Cerebral Ventricles/drug effects/physiology | 3 | 60.0 |
Mesocricetus | 3 | 1.0 |
Neuropeptide Y/administration & dosage/*pharmacology | 8 | 100.0 |
Peptide YY/administration & dosage/pharmacology | 2 | 100.0 |
Posture | 3 | 3.0 |
Aging/*physiology | 6 | 2.0 |
Body Weight/drug effects | 8 | 4.0 |
Rats, Inbred F344 | 2 | 0.0 |
Neoplasm Invasiveness | 3 | 0.0 |
Cytokines/metabolism | 2 | 0.0 |
Models, Biological | 7 | 0.0 |
Models, Molecular | 15 | 0.0 |
Multigene Family | 2 | 0.0 |
Neuropeptide Y/*chemistry | 3 | 100.0 |
Body Constitution | 3 | 2.0 |
*Body Weight | 2 | 3.0 |
Estradiol/blood | 4 | 0.0 |
Regression Analysis | 4 | 0.0 |
Anorexia Nervosa/*blood/metabolism | 2 | 66.0 |
Corticotropin-Releasing Hormone/*cerebrospinal fluid | 2 | 40.0 |
Appetite Depressants/*pharmacology | 2 | 50.0 |
Receptors, Neuropeptide Y/*antagonists & inhibitors/physiology | 3 | 100.0 |
Adipose Tissue/anatomy & histology | 2 | 7.0 |
Feeding Behavior/drug effects/*physiology | 2 | 66.0 |
Obesity/*physiopathology | 4 | 7.0 |
Rats, Inbred Strains | 23 | 2.0 |
Sex Characteristics | 5 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Neuropeptide Y/genetics/metabolism | 5 | 83.0 |
PC12 Cells | 4 | 1.0 |
Magnetic Resonance Spectroscopy | 7 | 1.0 |
Peptides/*chemistry | 2 | 4.0 |
Receptors, Neurokinin-1/metabolism | 2 | 40.0 |
Receptors, Neuropeptide Y/*genetics/metabolism | 3 | 100.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
*Immunohistochemistry | 2 | 2.0 |
Microscopy, Electron | 12 | 0.0 |
Chronic Disease | 6 | 0.0 |
Inflammation | 2 | 0.0 |
Eating/*drug effects/physiology | 2 | 50.0 |
Food Deprivation/physiology | 2 | 28.0 |
Nerve Tissue Proteins/*pharmacology | 7 | 7.0 |
Neuropeptides/*pharmacology | 9 | 16.0 |
Neurotransmitters/*pharmacology | 3 | 21.0 |
Adenosine Triphosphate/*pharmacology | 2 | 7.0 |
Vascular Resistance | 3 | 5.0 |
Gestational Age | 11 | 1.0 |
Tyrosine 3-Monooxygenase/*analysis | 9 | 25.0 |
Neurosecretory Systems/*physiology | 3 | 11.0 |
Rats, Inbred BN | 2 | 4.0 |
Reproduction/*physiology | 4 | 15.0 |
Peptide Fragments/metabolism | 3 | 0.0 |
Receptors, Neuropeptide Y/chemistry/classification/*metabolism | 2 | 100.0 |
Zebrafish | 2 | 1.0 |
Blood Vessels/innervation | 4 | 50.0 |
Calcitonin Gene-Related Peptide/*analysis | 8 | 47.0 |
Neurons, Afferent/*chemistry | 2 | 66.0 |
Skin/blood supply/*innervation | 2 | 100.0 |
Substance P/*analysis | 6 | 20.0 |
Sweat Glands/innervation | 2 | 100.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Membranes/metabolism | 3 | 6.0 |
Receptors, Neuropeptide Y/*antagonists & inhibitors/metabolism | 7 | 100.0 |
Consensus Sequence | 3 | 0.0 |
*Evolution, Molecular | 4 | 0.0 |
Fishes | 4 | 5.0 |
Peptide YY/chemistry/*genetics | 2 | 100.0 |
Xenopus laevis | 3 | 0.0 |
Mice, Obese | 3 | 6.0 |
Models, Genetic | 3 | 0.0 |
Neoplasm Staging | 7 | 0.0 |
Neuropeptide Y/immunology | 2 | 100.0 |
Vasoactive Intestinal Peptide/immunology | 2 | 100.0 |
Eating Disorders/physiopathology | 3 | 75.0 |
Biological Markers/analysis | 13 | 1.0 |
Immunohistochemistry/methods | 7 | 1.0 |
Nerve Fibers/ultrastructure | 6 | 40.0 |
Neurotransmitters/*analysis | 6 | 35.0 |
Phosphopyruvate Hydratase/analysis | 2 | 2.0 |
S100 Proteins/analysis | 3 | 1.0 |
Peptides/*genetics | 2 | 2.0 |
Predictive Value of Tests | 4 | 0.0 |
Survival Rate | 4 | 0.0 |
Transcription, Genetic | 9 | 0.0 |
Hypothalamo-Hypophyseal System/physiology | 2 | 6.0 |
Puberty/*physiology | 2 | 10.0 |
Electrocardiography | 3 | 0.0 |
Endothelins/blood | 3 | 21.0 |
Epinephrine/blood | 12 | 9.0 |
Heart Rate | 4 | 1.0 |
Neuropeptide Y/pharmacology/*physiology | 4 | 100.0 |
Pancreatic Polypeptide/pharmacology | 10 | 100.0 |
Peptide YY/pharmacology | 7 | 77.0 |
Feeding Behavior/drug effects | 3 | 23.0 |
Nuclear Magnetic Resonance, Biomolecular | 3 | 1.0 |
Protein Structure, Secondary | 5 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
*Multigene Family | 3 | 0.0 |
Neuropeptide Y/chemistry/*genetics | 3 | 100.0 |
Zebrafish/*genetics | 3 | 11.0 |
Embryo | 2 | 0.0 |
Mutation/physiology | 2 | 1.0 |
Organ Culture Techniques | 3 | 0.0 |
Arginine/analogs & derivatives/pharmacology | 10 | 33.0 |
Follicle Stimulating Hormone/blood | 4 | 0.0 |
Leptin/*analysis | 3 | 50.0 |
Luteinizing Hormone/blood | 5 | 0.0 |
Hypothalamus/*physiopathology | 2 | 11.0 |
Serotonin/blood | 2 | 5.0 |
Thyroxine/blood | 2 | 0.0 |
Triiodothyronine/blood | 2 | 0.0 |
Calcitonin Gene-Related Peptide/blood | 6 | 75.0 |
Endothelin-1/blood | 2 | 11.0 |
Hypothalamus/cytology/*metabolism | 2 | 33.0 |
Chromatography, Gel | 18 | 2.0 |
Peptide Fragments/analysis | 5 | 2.0 |
*Protein Processing, Post-Translational | 4 | 1.0 |
Sequence Analysis | 2 | 0.0 |
Thiolester Hydrolases/*metabolism | 3 | 37.0 |
Immunoenzyme Techniques | 30 | 0.0 |
Macaca fascicularis | 6 | 2.0 |
Nerve Tissue Proteins/metabolism | 6 | 2.0 |
Culture Techniques | 4 | 0.0 |
Hemodynamic Processes/*drug effects | 3 | 2.0 |
Probability | 2 | 0.0 |
Rats, Inbred SHR | 4 | 4.0 |
Rats, Wistar | 34 | 2.0 |
Cattle | 26 | 0.0 |
Amino Acid Substitution | 3 | 0.0 |
DNA/genetics | 4 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Protein Precursors/genetics | 4 | 4.0 |
Cell Membrane/metabolism | 9 | 0.0 |
Guanosine 5'-O-(3-Thiotriphosphate)/metabolism | 2 | 2.0 |
Peptides/metabolism | 16 | 7.0 |
Appetite | 2 | 25.0 |
Forearm/*blood supply | 2 | 9.0 |
Hypertension/*physiopathology | 4 | 6.0 |
Norepinephrine/*pharmacology | 6 | 31.0 |
Regional Blood Flow/drug effects | 11 | 10.0 |
Vasoconstrictor Agents/*pharmacology | 4 | 10.0 |
Hypothalamus/chemistry/*physiology | 2 | 50.0 |
Alleles | 8 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Mexican Americans/*genetics | 2 | 8.0 |
Nuclear Family | 2 | 0.0 |
Pedigree | 3 | 0.0 |
*Aging | 2 | 1.0 |
Obesity/blood | 2 | 5.0 |
Progesterone/blood | 3 | 1.0 |
Ganglia, Spinal/cytology/metabolism | 2 | 20.0 |
Medulla Oblongata/cytology/*metabolism | 2 | 100.0 |
Neuropeptide Y/analogs & derivatives/*pharmacology | 5 | 100.0 |
Pyrimidines/pharmacology | 4 | 3.0 |
Bladder/*metabolism | 2 | 15.0 |
Chromosome Mapping | 9 | 0.0 |
Chromosomes, Human, Pair 7/*genetics | 2 | 1.0 |
Genetic Predisposition to Disease | 4 | 0.0 |
Sympathetic Nervous System/*physiology | 9 | 18.0 |
Fasting | 3 | 0.0 |
Protein Precursors/*genetics | 2 | 1.0 |
Triglycerides/*blood | 2 | 0.0 |
Mutagenesis, Site-Directed | 8 | 0.0 |
Aging/metabolism | 2 | 1.0 |
Gonadorelin/*secretion | 4 | 57.0 |
Receptors, Neuropeptide Y/physiology | 2 | 66.0 |
Blood Pressure/*physiology | 3 | 3.0 |
Pregnancy/*physiology | 2 | 4.0 |
Phospholipase C/antagonists & inhibitors | 2 | 13.0 |
Receptors, Neuropeptide Y/*drug effects | 3 | 100.0 |
Peptide YY/*pharmacology | 2 | 28.0 |
Nifedipine/pharmacology | 3 | 7.0 |
Iodine Radioisotopes/diagnostic use | 7 | 2.0 |
Membranes/drug effects/metabolism | 2 | 40.0 |
Receptors, Neuropeptide Y/antagonists & inhibitors/*metabolism | 3 | 100.0 |
Benzazepines/*pharmacology | 2 | 13.0 |
Dogs | 21 | 1.0 |
NG-Nitroarginine Methyl Ester/pharmacology | 2 | 4.0 |
Skin/blood supply | 2 | 3.0 |
Vasodilation/*drug effects | 3 | 7.0 |
*Chromosome Mapping/methods | 2 | 10.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 6 | 0.0 |
Psychiatric Status Rating Scales | 7 | 3.0 |
Severity of Illness Index | 2 | 0.0 |
*Eating | 2 | 3.0 |
Obesity/etiology | 2 | 22.0 |
Gastrointestinal Hormones/*metabolism | 3 | 12.0 |
Recombination, Genetic | 2 | 0.0 |
Sheep | 9 | 1.0 |
Genetic Markers | 3 | 0.0 |
Nerve Tissue Proteins/*analysis | 11 | 13.0 |
Neurons/chemistry | 2 | 8.0 |
Organ Specificity | 11 | 0.0 |
Energy Metabolism/*physiology | 7 | 7.0 |
Atrial Natriuretic Factor/*analysis | 2 | 50.0 |
Heart Atria | 3 | 10.0 |
Neuropeptides/*analysis | 42 | 54.0 |
Neurotensin/analysis | 3 | 30.0 |
DNA, Complementary | 4 | 0.0 |
Signal Transduction/physiology | 4 | 0.0 |
Phosphopyruvate Hydratase/metabolism | 2 | 3.0 |
Pro-Opiomelanocortin/physiology | 2 | 100.0 |
Prolactin/blood | 4 | 0.0 |
Endothelium, Vascular/*drug effects/physiology | 2 | 11.0 |
Neuropeptide Y/*pharmacology/physiology | 3 | 100.0 |
Vasoconstrictor Agents/pharmacology | 5 | 13.0 |
Acetylcholinesterase/analysis | 4 | 11.0 |
Autonomic Nervous System/*anatomy & histology | 3 | 60.0 |
Microscopy, Fluorescence | 6 | 0.0 |
Thiolester Hydrolases/analysis | 15 | 42.0 |
*Cerebrovascular Circulation | 4 | 11.0 |
Substance P/*blood | 3 | 25.0 |
Molecular Structure | 3 | 0.0 |
Peptide Fragments/*chemistry | 2 | 6.0 |
Limbic System/*physiopathology | 2 | 33.0 |
Neuropeptide Y/chemistry/*pharmacology | 2 | 100.0 |
Colon/*chemistry | 2 | 9.0 |
Galanin/analysis | 8 | 80.0 |
Mice, Inbred NOD | 2 | 0.0 |
Somatostatin/analysis | 14 | 24.0 |
Stomach/*chemistry | 2 | 33.0 |
Blotting, Southern | 4 | 0.0 |
DNA | 4 | 0.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Nerve Tissue Proteins/analysis | 8 | 10.0 |
Adrenergic Fibers/*chemistry | 2 | 66.0 |
Neuropeptide Y/*analysis/immunology | 2 | 100.0 |
Orchiectomy | 3 | 2.0 |
*Gene Expression Regulation | 10 | 0.0 |
Receptors, Neuropeptide Y/biosynthesis/*genetics | 2 | 100.0 |
Antibodies | 7 | 1.0 |
Neuropeptide Y/analysis/immunology | 2 | 100.0 |
Immune Sera/immunology | 2 | 1.0 |
Peptide Fragments/chemistry/metabolism | 2 | 1.0 |
Peptide YY/metabolism | 8 | 66.0 |
Cell Aggregation | 2 | 1.0 |
Neurons/cytology | 3 | 6.0 |
Specimen Handling | 3 | 3.0 |
Trypsin | 2 | 1.0 |
Growth Hormone/*secretion | 6 | 5.0 |
Hypothalamus/*drug effects/secretion | 2 | 28.0 |
Peptides/*pharmacology | 8 | 3.0 |
Leptin | 22 | 21.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Nerve Fibers/chemistry | 5 | 31.0 |
Biological Transport/drug effects | 2 | 0.0 |
Calcium Channel Blockers/*pharmacology | 2 | 5.0 |
Peptide Fragments/pharmacology | 10 | 4.0 |
Peptides/pharmacology | 11 | 5.0 |
Peptides, Cyclic/pharmacology | 2 | 5.0 |
Potassium/pharmacology | 5 | 8.0 |
Hypothalamus/*cytology | 2 | 40.0 |
Galanin/*physiology | 3 | 60.0 |
Receptors, Neuropeptide Y/chemistry/*genetics/*metabolism | 2 | 100.0 |
Axons/physiology | 2 | 4.0 |
Electroencephalography/drug effects | 2 | 8.0 |
Blood Pressure/physiology | 3 | 1.0 |
Catecholamines/blood | 3 | 6.0 |
Kainic Acid | 3 | 18.0 |
Up-Regulation/physiology | 2 | 1.0 |
Forecasting | 4 | 1.0 |
Neuropeptides/physiology | 4 | 14.0 |
Dietary Fats | 2 | 5.0 |
Neurotransmitters/physiology | 5 | 15.0 |
Appetite/*drug effects | 2 | 25.0 |
Body Temperature | 2 | 2.0 |
Insulin-Like Growth Factor I/metabolism | 2 | 1.0 |
Recombinant Proteins/pharmacology | 5 | 0.0 |
Hydrocortisone/secretion | 2 | 8.0 |
Somatotropin-Releasing Hormone/pharmacology | 3 | 6.0 |
Receptors, Neuropeptide Y/genetics | 4 | 66.0 |
*Transcription, Genetic | 5 | 0.0 |
Anticonvulsants/*pharmacology | 3 | 15.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Age Factors | 8 | 0.0 |
Dexamethasone/diagnostic use | 3 | 7.0 |
Stress, Psychological/blood | 2 | 33.0 |
beta-Endorphin/blood | 6 | 17.0 |
*Body Mass Index | 2 | 2.0 |
Adenosine Triphosphate/*physiology | 2 | 16.0 |
Adrenergic alpha-Antagonists/pharmacology | 4 | 22.0 |
Prazosin/pharmacology | 3 | 33.0 |
Sympathetic Nervous System/drug effects/physiology | 2 | 33.0 |
Vasomotor System/drug effects/*physiology | 2 | 100.0 |
Anesthesia | 3 | 9.0 |
Peptide Fragments/*pharmacology | 8 | 4.0 |
Receptors, Neuropeptide Y/*agonists | 2 | 100.0 |
Schizophrenia/*therapy | 2 | 50.0 |
*Kidney Transplantation | 2 | 0.0 |
Proteins/*metabolism | 4 | 0.0 |
Renal Dialysis | 4 | 1.0 |
Neuropeptide Y/blood/*pharmacology | 2 | 100.0 |
Vasoconstriction/*drug effects | 13 | 36.0 |
Vasomotor System/*physiology | 3 | 33.0 |
Brain Chemistry | 9 | 3.0 |
Calcium-Binding Protein, Vitamin D-Dependent/analysis | 2 | 14.0 |
Fluorescent Antibody Technique | 33 | 1.0 |
Fluorescent Dyes | 4 | 1.0 |
Eating/physiology | 8 | 14.0 |
Hypothalamo-Hypophyseal System/*physiology | 4 | 16.0 |
Pituitary-Adrenal System/*physiology | 3 | 21.0 |
*Micelles | 2 | 20.0 |
Protein Folding | 2 | 0.0 |
*Protein Structure, Secondary | 2 | 1.0 |
Cerebrovascular Circulation/physiology | 2 | 9.0 |
Microcirculation/physiology | 2 | 6.0 |
RNA, Messenger/*metabolism | 3 | 0.0 |
Evaluation Studies | 2 | 0.0 |
Neuropeptide Y/*genetics/*physiology | 3 | 100.0 |
Obesity/genetics/metabolism | 2 | 14.0 |
Nerve Fibers/*chemistry | 11 | 64.0 |
Osmolar Concentration | 11 | 1.0 |
Double-Blind Method | 9 | 0.0 |
Anura | 2 | 13.0 |
Blood Pressure/*drug effects/physiology | 2 | 15.0 |
Muscle, Smooth, Vascular/drug effects/physiology | 3 | 33.0 |
France | 2 | 0.0 |
Obesity/genetics/*physiopathology | 2 | 28.0 |
Antidepressive Agents/*therapeutic use | 2 | 13.0 |
Cold | 3 | 2.0 |
Neuropeptide Y/antagonists & inhibitors/*physiology | 2 | 100.0 |
Propranolol/pharmacology | 3 | 6.0 |
*Skin Physiology | 2 | 5.0 |
Sympathetic Nervous System/physiology | 4 | 14.0 |
Vasoconstriction/*physiology | 3 | 20.0 |
Vasodilator Agents/pharmacology | 2 | 3.0 |
Vasomotor System/drug effects/physiology | 2 | 66.0 |
Yohimbine/pharmacology | 2 | 22.0 |
Endothelin-1/*blood | 2 | 9.0 |
Adipose Tissue/metabolism | 4 | 3.0 |
Puberty/physiology | 2 | 13.0 |
Feeding Behavior | 2 | 8.0 |
Appetite Regulation/*physiology | 4 | 28.0 |
Diabetes Mellitus, Experimental/physiopathology | 2 | 33.0 |
Naphthalenes/*pharmacology | 2 | 15.0 |
Pyrimidines/*pharmacology | 2 | 3.0 |
Triglycerides/blood | 2 | 0.0 |
Aging/*metabolism | 3 | 1.0 |
Colon/metabolism | 2 | 1.0 |
Galanin/metabolism | 3 | 37.0 |
Somatostatin/metabolism | 5 | 10.0 |
Cadaver | 2 | 0.0 |
Muscle, Smooth/chemistry/innervation | 2 | 40.0 |
Norepinephrine/analysis | 3 | 17.0 |
Exercise/*physiology | 7 | 1.0 |
Kidney Failure, Chronic/blood/therapy | 2 | 6.0 |
*Renal Dialysis | 4 | 0.0 |
Rest/*physiology | 2 | 20.0 |
Uremia/*blood | 2 | 6.0 |
Acetylcholinesterase/*metabolism | 3 | 1.0 |
Tyrosine 3-Monooxygenase/*metabolism | 2 | 2.0 |
Neuropeptide Y | 43 | 89.0 |
Vasectomy | 2 | 18.0 |
RNA, Messenger/*biosynthesis | 4 | 1.0 |
Receptors, Neuropeptide Y/*biosynthesis | 5 | 100.0 |
Bombesin/analysis | 2 | 11.0 |
Enkephalins/analysis | 6 | 54.0 |
Inositol Phosphates/*pharmacology | 2 | 40.0 |
Myocardium/cytology | 2 | 6.0 |
Paraventricular Hypothalamic Nucleus/drug effects/metabolism | 2 | 50.0 |
RNA, Messenger/*genetics/*metabolism | 2 | 4.0 |
Ovariectomy | 7 | 5.0 |
Brain-Derived Neurotrophic Factor/pharmacology | 3 | 6.0 |
Neuropeptide Y/*genetics/metabolism | 2 | 66.0 |
Tetradecanoylphorbol Acetate/pharmacology | 7 | 0.0 |
Epinephrine/*blood | 5 | 17.0 |
Norepinephrine/*blood | 12 | 20.0 |
Neuropeptide Y/metabolism/pharmacology | 4 | 100.0 |
Cell Division | 2 | 0.0 |
Gene Expression | 11 | 0.0 |
Prognosis | 4 | 0.0 |
Neuropeptide Y/analogs & derivatives/pharmacology | 3 | 100.0 |
Receptors, Neuropeptide Y/drug effects/*physiology | 2 | 100.0 |
Estradiol/pharmacology | 2 | 0.0 |
Guanine Nucleotides/pharmacology | 2 | 16.0 |
Neuropeptide Y/analogs & derivatives/metabolism | 2 | 100.0 |
Receptors, Neuropeptide Y/drug effects/*metabolism | 3 | 100.0 |
Human Growth Hormone/secretion | 2 | 8.0 |
Hyperplasia | 2 | 0.0 |
Neuropeptide Y/immunology/*metabolism | 2 | 100.0 |
Arginine/analogs & derivatives/metabolism | 2 | 33.0 |
DNA Primers/genetics | 3 | 0.0 |
Spleen/metabolism | 2 | 1.0 |
Vasoconstriction/drug effects | 6 | 16.0 |
Genetic Vectors | 4 | 0.0 |
Receptors, Neuropeptide Y/chemistry/*genetics/metabolism | 2 | 100.0 |
Jejunum/drug effects/metabolism | 2 | 66.0 |
Hormones/physiology | 2 | 6.0 |
Intestines/metabolism | 3 | 2.0 |
Peptide YY/physiology | 2 | 100.0 |
Amino Acids/analysis | 2 | 0.0 |
Molecular Weight | 4 | 0.0 |
Affinity Labels | 2 | 3.0 |
Fluorescent Antibody Technique, Direct | 2 | 1.0 |
Muscle, Smooth/innervation | 4 | 36.0 |
Neuropeptides/*analysis/physiology | 2 | 100.0 |
Diazepam/pharmacology | 2 | 11.0 |
Receptors, Neuropeptide Y/antagonists & inhibitors/*physiology | 3 | 100.0 |
Dopamine beta-Hydroxylase/analysis | 13 | 59.0 |
Nerve Fibers/pathology | 2 | 8.0 |
Parasympathetic Nervous System/*metabolism | 2 | 33.0 |
Sympathetic Nervous System/*metabolism | 5 | 62.0 |
Autonomic Nervous System/physiology | 2 | 20.0 |
Homeostasis/physiology | 3 | 5.0 |
Neuropeptide Y/biosynthesis/genetics/*physiology | 3 | 100.0 |
Adenylate Cyclase/metabolism | 6 | 4.0 |
*Embryonic and Fetal Development | 6 | 5.0 |
Nitric-Oxide Synthase/analysis | 2 | 13.0 |
Myocardium/metabolism | 2 | 0.0 |
Peptide Fragments/metabolism/pharmacology | 2 | 6.0 |
Muscle, Smooth, Vascular/*physiology | 2 | 11.0 |
Norepinephrine/metabolism | 7 | 14.0 |
Cyclic AMP/antagonists & inhibitors | 3 | 50.0 |
Stereoisomerism | 3 | 0.0 |
*Models, Molecular | 2 | 1.0 |
Food Deprivation/*physiology | 3 | 37.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
GTP-Binding Proteins/*physiology | 2 | 1.0 |
Receptors, Neuropeptide Y/agonists/*metabolism | 2 | 100.0 |
Rhinitis, Allergic, Perennial/*physiopathology | 2 | 100.0 |
Neuroblastoma/metabolism | 5 | 8.0 |
Peptides, Cyclic/*pharmacology | 3 | 14.0 |
Tumor Cells, Cultured/drug effects/metabolism | 2 | 1.0 |
Protein Precursors/pharmacology | 2 | 28.0 |
Vagus Nerve/drug effects/physiology | 2 | 66.0 |
Nitric Oxide/physiology | 2 | 4.0 |
Hypertrophy | 2 | 1.0 |
Duodenum/*metabolism | 2 | 10.0 |
Mice, Inbred Strains | 2 | 0.0 |
Mice, Mutant Strains | 3 | 0.0 |
Mutation/genetics | 2 | 0.0 |
*Blood Pressure | 5 | 4.0 |
Diabetes Mellitus, Type 2/blood/*physiopathology | 2 | 10.0 |
Gastric Acid/*secretion | 2 | 3.0 |
Receptors, Gastrointestinal Hormone/*metabolism | 2 | 7.0 |
Peptides/*blood | 3 | 4.0 |
Lithium/*pharmacology | 2 | 12.0 |
Neuropeptide Y/blood/*physiology | 5 | 100.0 |
Cell Membrane/metabolism/ultrastructure | 2 | 3.0 |
Perfusion | 4 | 1.0 |
Staining and Labeling | 5 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Hypothalamus/physiology | 3 | 10.0 |
Blood Pressure | 10 | 1.0 |
Hypertension/blood/*etiology/physiopathology | 2 | 100.0 |
Chromogranins/blood | 2 | 33.0 |
Growth Hormone/blood | 2 | 0.0 |
Corticotropin-Releasing Hormone/blood | 2 | 12.0 |
Hypothalamo-Hypophyseal System/*physiopathology | 3 | 5.0 |
Pituitary-Adrenal System/*physiopathology | 2 | 8.0 |
Neuropeptide Y/*administration & dosage | 2 | 66.0 |
Cross Reactions | 4 | 0.0 |
Glasgow Coma Scale | 2 | 7.0 |
Spinal Puncture | 4 | 33.0 |
Nerve Growth Factors/pharmacology | 3 | 3.0 |
Protein Kinase C/antagonists & inhibitors/metabolism | 2 | 2.0 |
Axons/ultrastructure | 2 | 9.0 |
Dendrites/ultrastructure | 2 | 22.0 |
Immune Sera | 7 | 2.0 |
Microscopy, Immunoelectron | 11 | 2.0 |
Receptors, Neuropeptide Y/*analysis | 2 | 66.0 |
Norepinephrine/physiology | 3 | 18.0 |
Inositol 1,4,5-Trisphosphate/metabolism | 3 | 5.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Corticosterone/blood | 2 | 5.0 |
Hypothalamus/drug effects/*metabolism | 3 | 37.0 |
Proteins/*pharmacology | 2 | 2.0 |
Obesity, Morbid/*genetics | 2 | 18.0 |
Polymorphism, Genetic/*genetics | 4 | 0.0 |
Neuropeptide Y/*secretion | 2 | 100.0 |
Motor Activity/drug effects | 3 | 5.0 |
Naloxone/pharmacology | 2 | 4.0 |
Capsaicin/pharmacology | 3 | 8.0 |
Peptides/*physiology | 2 | 4.0 |
Bladder/*innervation | 3 | 60.0 |
Ureter/*innervation | 4 | 80.0 |
Neuropeptide Y/*analogs & derivatives/pharmacology | 3 | 100.0 |
Choline O-Acetyltransferase/analysis | 4 | 8.0 |
Adenosine/pharmacology | 2 | 8.0 |
Chlorides/*metabolism | 2 | 2.0 |
Potassium Channels/drug effects/*physiology | 2 | 14.0 |
Body Weight/physiology | 4 | 5.0 |
Protein Binding/genetics | 2 | 0.0 |
Electroshock | 2 | 15.0 |
Embryonic and Fetal Development/physiology | 2 | 2.0 |
Receptors, Neuropeptide Y/chemistry/genetics | 2 | 100.0 |
Xenopus | 2 | 0.0 |
Xenopus laevis/*genetics | 2 | 7.0 |
Neuropeptides/metabolism/*physiology | 2 | 22.0 |
NADPH Dehydrogenase/analysis | 2 | 13.0 |
Dopamine beta-Hydroxylase/metabolism | 3 | 12.0 |
Arginine/*analogs & derivatives/*pharmacology | 2 | 66.0 |
Somatostatin/physiology | 3 | 14.0 |
Vasoactive Intestinal Peptide/physiology | 3 | 18.0 |
Enkephalin, Methionine/analysis | 4 | 40.0 |
Protein Precursors/*metabolism | 4 | 5.0 |
*Exercise | 3 | 2.0 |
*Vasoconstriction | 2 | 50.0 |
Enkephalin, Leucine/analysis | 3 | 60.0 |
Neuropeptides/analysis | 7 | 36.0 |
Glucose Clamp Technique | 3 | 2.0 |
Neuropeptide Y/metabolism/*pharmacology | 4 | 100.0 |
Vasoconstriction | 4 | 23.0 |
European Continental Ancestry Group | 2 | 0.0 |
Myocardium/*metabolism | 4 | 1.0 |
Nerve Tissue Proteins/*metabolism | 5 | 1.0 |
*Heart Rate | 2 | 4.0 |
Calcitonin Gene-Related Peptide/*pharmacology | 3 | 23.0 |
Substance P/*pharmacology | 3 | 9.0 |
Secretory Rate/drug effects | 3 | 3.0 |
Fetus | 5 | 0.0 |
Acetylcholine/pharmacology | 5 | 7.0 |
Veins/drug effects | 2 | 40.0 |
Neurons/*chemistry | 3 | 9.0 |
Neuropeptide Y/*antagonists & inhibitors | 2 | 100.0 |
Gallbladder/*innervation | 3 | 60.0 |
NADPH Dehydrogenase/*metabolism | 3 | 33.0 |
Computer Simulation | 4 | 1.0 |
Electrophysiology | 7 | 1.0 |
Patch-Clamp Techniques | 5 | 1.0 |
Peptide YY | 46 | 40.0 |
Synaptic Transmission/*drug effects | 5 | 31.0 |
RNA, Messenger | 2 | 0.0 |
Calcium/*metabolism | 5 | 0.0 |
*Digestive Physiology | 4 | 12.0 |
Diet | 4 | 1.0 |
Neurotransmitters/*physiology | 3 | 9.0 |
Obesity/*etiology | 2 | 33.0 |
Nasal Mucosa/*innervation | 4 | 80.0 |
Vasoactive Intestinal Peptide/*analysis | 13 | 22.0 |
Receptors, Neuropeptide/metabolism | 2 | 28.0 |
Peptides/metabolism/pharmacology | 2 | 12.0 |
Glucose Tolerance Test | 3 | 0.0 |
Gastrin-Releasing Peptide | 4 | 4.0 |
Interleukin-1/*biosynthesis | 2 | 1.0 |
Interleukin-6/*biosynthesis | 2 | 1.0 |
Somatostatin/*pharmacology | 2 | 4.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 2 | 0.0 |
Vasoactive Intestinal Peptide/*pharmacology | 7 | 7.0 |
Feedback, Biochemical | 2 | 4.0 |
*Obesity | 2 | 3.0 |
Muscle Contraction/drug effects | 15 | 16.0 |
Muscle, Smooth, Vascular/drug effects | 4 | 17.0 |
*Evolution | 5 | 2.0 |
Primates | 2 | 2.0 |
RNA, Messenger/analysis/biosynthesis | 3 | 1.0 |
Recombinant Proteins/biosynthesis/chemistry/metabolism | 2 | 2.0 |
Pituitary Neoplasms/*secretion | 2 | 4.0 |
Reproduction | 2 | 9.0 |
Hypothalamus/drug effects/metabolism | 2 | 18.0 |
Neuroblastoma | 9 | 4.0 |
Nerve Growth Factors/*pharmacology | 3 | 2.0 |
Adrenergic alpha-Agonists/pharmacology | 2 | 8.0 |
Clonidine/pharmacology | 2 | 13.0 |
Iodine Radioisotopes | 6 | 1.0 |
Receptors, Neuropeptide Y/drug effects/genetics/*physiology | 2 | 100.0 |
Appetite Stimulants/therapeutic use | 2 | 50.0 |
Cardiovascular Diseases/drug therapy | 2 | 18.0 |
Schizophrenia/drug therapy | 3 | 30.0 |
Nasal Mucosa/*drug effects | 2 | 66.0 |
Blood Pressure/*drug effects | 3 | 1.0 |
Feeding Behavior/*drug effects | 7 | 43.0 |
Cerebral Cortex/*cytology | 3 | 18.0 |
NADPH Dehydrogenase/*analysis | 2 | 50.0 |
Nitric-Oxide Synthase/metabolism | 2 | 1.0 |
Gastrointestinal Hormones/metabolism | 3 | 42.0 |
Satiety Response/physiology | 2 | 22.0 |
Point Mutation | 2 | 0.0 |
Capillary Permeability | 2 | 2.0 |
Microcirculation | 2 | 0.0 |
Heart Failure, Congestive/*blood | 4 | 26.0 |
Aldosterone/blood | 2 | 1.0 |
Renin/blood | 4 | 1.0 |
Calcium/*physiology | 2 | 1.0 |
Protein Kinase Inhibitors | 2 | 1.0 |
Dependovirus/genetics | 2 | 6.0 |
Hydroxyindoleacetic Acid/cerebrospinal fluid | 2 | 14.0 |
Neuropeptide Y/blood/*cerebrospinal fluid | 2 | 66.0 |
Chromogranins/analysis | 3 | 5.0 |
Insulin/analysis | 3 | 13.0 |
Cell Membrane Permeability | 2 | 1.0 |
Skin/*chemistry | 2 | 6.0 |
Leptin/*pharmacology/physiology | 2 | 66.0 |
Cercopithecus aethiops | 2 | 0.0 |
Gene Library | 2 | 0.0 |
Kidney | 2 | 0.0 |
Proteins/genetics/metabolism | 2 | 1.0 |
Exercise Test | 9 | 3.0 |
*Exertion | 3 | 1.0 |
Rest | 2 | 4.0 |
Second Messenger Systems/*physiology | 2 | 7.0 |
Receptors, Gastrointestinal Hormone/classification/*genetics/metabolism | 2 | 100.0 |
Receptors, Neuropeptide Y/classification/*genetics/metabolism | 2 | 100.0 |
Hippocampus/*metabolism | 3 | 4.0 |
GTP-Binding Proteins/physiology | 2 | 3.0 |
Neuropeptide Y/*analogs & derivatives/*pharmacology | 2 | 100.0 |
Calcium/physiology | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
GTP-Binding Proteins/*metabolism | 2 | 0.0 |
Adrenal Gland Neoplasms/*metabolism | 5 | 31.0 |
Pheochromocytoma/*metabolism | 6 | 42.0 |
Synaptophysin/analysis | 2 | 5.0 |
Body Temperature/drug effects | 2 | 5.0 |
Obesity/physiopathology | 4 | 14.0 |
Receptors, Neuropeptide Y/*agonists/*antagonists & inhibitors | 2 | 100.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Restriction Mapping | 4 | 0.0 |
Leukemia, Erythroblastic, Acute | 3 | 3.0 |
Glial Fibrillary Acidic Protein/analysis | 3 | 1.0 |
Atrial Natriuretic Factor/*blood | 2 | 3.0 |
Peptides/blood | 3 | 8.0 |
Brain/metabolism/ultrastructure | 2 | 28.0 |
Nerve Degeneration | 3 | 4.0 |
Neuropeptides/*cerebrospinal fluid | 4 | 57.0 |
Chemistry, Physical | 2 | 1.0 |
Hela Cells | 4 | 0.0 |
Fura-2 | 2 | 7.0 |
Heart/drug effects | 4 | 8.0 |
Norepinephrine/*metabolism | 3 | 8.0 |
Epithelium/chemistry | 2 | 1.0 |
Heart/*innervation | 3 | 17.0 |
Axons/metabolism/ultrastructure | 2 | 14.0 |
Evoked Potentials/drug effects | 3 | 21.0 |
Autopsy | 3 | 1.0 |
Models, Neurological | 2 | 1.0 |
Neurons/*pathology | 3 | 4.0 |
Peptides/blood/*pharmacology | 2 | 28.0 |
Neuropeptide Y/metabolism/pharmacology/*physiology | 2 | 100.0 |
Pancreatic Polypeptide/*genetics | 2 | 100.0 |
Bladder/chemistry/*innervation | 2 | 100.0 |
Peptides/*immunology | 2 | 2.0 |
Injections | 2 | 1.0 |
Peptide PHI/analysis | 6 | 66.0 |
Hemodynamic Processes | 7 | 3.0 |
Substance P/blood | 3 | 30.0 |
Diabetes Mellitus, Experimental/*metabolism | 2 | 11.0 |
Energy Metabolism/physiology | 2 | 3.0 |
Neural Pathways/metabolism | 2 | 66.0 |
Syndrome | 2 | 0.0 |
Acute Disease | 2 | 0.0 |
Argipressin/blood | 5 | 3.0 |
Corticotropin/blood | 2 | 1.0 |
Gastrointestinal Hormones/pharmacology | 2 | 22.0 |
Intracellular Membranes/metabolism | 2 | 1.0 |
Denervation | 2 | 5.0 |
Galanin | 11 | 28.0 |
Peptides/analysis | 5 | 6.0 |
Vascular Resistance/physiology | 2 | 9.0 |
Conflict (Psychology) | 2 | 22.0 |
Hirschsprung Disease/*pathology | 2 | 20.0 |
Clonidine/*pharmacology | 2 | 8.0 |
Colon/*innervation | 2 | 15.0 |
Nervous System/metabolism | 2 | 9.0 |
Nitric-Oxide Synthase | 2 | 5.0 |
Synovial Fluid/*metabolism | 4 | 16.0 |
Nerve Fibers/*physiology/ultrastructure | 2 | 40.0 |
Norepinephrine/*analysis | 2 | 50.0 |
Motilin/blood | 2 | 11.0 |
Pilot Projects | 3 | 0.0 |
Neuroblastoma/*metabolism | 6 | 10.0 |
Plasmids | 6 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Oligonucleotide Probes | 2 | 0.0 |
Exercise | 2 | 1.0 |
Vascular Resistance/drug effects | 2 | 3.0 |
Cyclic AMP/*metabolism | 2 | 0.0 |
Trachea/drug effects/*physiology | 2 | 28.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Exercise/physiology | 2 | 3.0 |
Dexamethasone/pharmacology | 3 | 0.0 |
Luteinizing Hormone/*secretion | 3 | 11.0 |
MSH/analysis | 2 | 28.0 |
Angiotensin II/pharmacology | 2 | 2.0 |
*Pertussis Toxin | 2 | 6.0 |
Terpenes/pharmacology | 2 | 7.0 |
Thapsigargin | 3 | 10.0 |
Virulence Factors, Bordetella/*pharmacology | 2 | 10.0 |
Epinephrine/pharmacology | 3 | 3.0 |
Oxygen Consumption/drug effects | 2 | 5.0 |
Splanchnic Circulation/*drug effects | 2 | 66.0 |
Carbon Dioxide/metabolism | 2 | 6.0 |
Neurotransmitters/analysis | 2 | 40.0 |
Arteries/innervation | 3 | 60.0 |
Arthritis/*metabolism | 2 | 28.0 |
Knee Joint/*metabolism | 2 | 40.0 |
Neuropeptides/blood/cerebrospinal fluid/*metabolism | 2 | 100.0 |
Buffers | 2 | 1.0 |
Jugular Veins | 3 | 21.0 |
Autonomic Nervous System/physiopathology | 2 | 7.0 |
Cell Line, Tumor | 3 | 0.0 |
Interneurons/*metabolism | 2 | 40.0 |
Postmortem Changes | 6 | 8.0 |
Diabetes Mellitus/*pathology | 2 | 66.0 |
Arteries/drug effects | 3 | 25.0 |
Muscle, Smooth, Vascular/*drug effects | 4 | 21.0 |
Neuropeptide Y/*analogs & derivatives/metabolism/*pharmacology | 2 | 100.0 |
Cyclic AMP/*biosynthesis | 2 | 7.0 |
*Circadian Rhythm | 3 | 1.0 |
Fasting/physiology | 2 | 12.0 |
Insulin/*physiology | 2 | 4.0 |
Stress/physiopathology | 2 | 8.0 |
Tumor Markers, Biological/*blood | 5 | 1.0 |
Cerebral Cortex/*pathology | 2 | 6.0 |
Neuropeptide Y/immunology/*physiology | 2 | 100.0 |
Synaptic Transmission/drug effects | 2 | 7.0 |
Vas Deferens/drug effects/*innervation | 2 | 100.0 |
Cats | 18 | 5.0 |
Neurotransmitters/*metabolism | 2 | 6.0 |
Behavior, Animal/drug effects | 5 | 10.0 |
*Brain Chemistry | 7 | 4.0 |
Corticotropin-Releasing Hormone/analysis | 2 | 66.0 |
Drug Administration Schedule | 2 | 0.0 |
Serotonin/metabolism | 2 | 2.0 |
Neuropeptide Y/*immunology | 3 | 100.0 |
Skin/*innervation | 4 | 19.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Calcitonin Gene-Related Peptide/chemistry | 2 | 50.0 |
Bicarbonates | 2 | 25.0 |
Kidney Failure, Chronic/blood/physiopathology/therapy | 2 | 100.0 |
MSH/blood | 2 | 66.0 |
Renal Dialysis/adverse effects/*methods | 2 | 33.0 |
Heart Failure, Congestive/drug therapy/*physiopathology | 2 | 22.0 |
Receptors, Neuropeptide/*genetics/metabolism | 2 | 40.0 |
Myocardial Infarction/*blood | 2 | 3.0 |
Glycoconjugates/metabolism | 2 | 18.0 |
Neuropeptide Y/*analogs & derivatives | 2 | 100.0 |
Receptors, Neuropeptide Y | 28 | 84.0 |
Receptors, Neurotransmitter/*physiology | 2 | 25.0 |
Ureter/*innervation/physiology | 2 | 100.0 |
Glycerol/blood | 2 | 5.0 |
Lactates/blood | 2 | 2.0 |
Oxygen Consumption | 2 | 0.0 |
Gastrointestinal Hormones/*pharmacology | 3 | 10.0 |
Muscle, Smooth/drug effects | 3 | 15.0 |
Vagotomy | 2 | 14.0 |
Regional Blood Flow/physiology | 2 | 4.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Neurokinin A/pharmacology | 2 | 25.0 |
Lower Body Negative Pressure | 2 | 16.0 |
Norepinephrine/blood/pharmacology | 2 | 66.0 |
Autonomic Nervous System/*physiology | 2 | 15.0 |
Receptors, Neurotransmitter/*metabolism | 10 | 35.0 |
*Synaptic Transmission | 3 | 30.0 |
DNA Probes | 2 | 0.0 |
Estradiol/*blood | 2 | 1.0 |
Neuropeptide Y/analysis/*physiology | 2 | 100.0 |
Receptors, Neurotransmitter/*drug effects/metabolism | 2 | 66.0 |
Chromaffin System/*metabolism | 2 | 100.0 |
Catecholamines/*metabolism | 2 | 3.0 |
Receptors, Neurotransmitter/metabolism | 2 | 11.0 |
Regional Blood Flow | 2 | 1.0 |
Adrenal Medulla/*metabolism | 2 | 25.0 |
Nerve Fibers/*chemistry/enzymology | 2 | 100.0 |
Behavior, Animal/*physiology | 2 | 7.0 |
Feeding Behavior/physiology | 3 | 23.0 |
Cerebral Ventricles/drug effects/*physiology | 2 | 20.0 |
Drinking Behavior/*drug effects | 2 | 100.0 |
Muscle Contraction/*drug effects | 2 | 8.0 |
Neuropeptide Y/analysis/*pharmacology | 2 | 100.0 |
Uterus/*blood supply | 2 | 8.0 |
Muscle, Smooth, Vascular/innervation | 2 | 100.0 |
Tetrodotoxin/pharmacology | 3 | 8.0 |
Neurons/enzymology | 2 | 4.0 |
Dioxanes/pharmacology | 2 | 66.0 |
Idazoxan | 2 | 100.0 |
Pancreatic Polypeptide/*analysis | 2 | 22.0 |
Peptides/*analysis | 2 | 2.0 |
Cations, Divalent/pharmacology | 2 | 5.0 |
Succinimides/diagnostic use | 2 | 50.0 |
Adrenal Gland Neoplasms/blood | 2 | 100.0 |
Action Potentials/drug effects | 2 | 5.0 |
Synapses/*drug effects | 2 | 50.0 |
Sampling Studies | 2 | 1.0 |
Isoproterenol/pharmacology | 5 | 4.0 |
Enkephalin, Methionine/metabolism | 2 | 28.0 |
Muscles/innervation | 3 | 18.0 |
Calcitonin/metabolism | 3 | 25.0 |
Nerve Fibers/*analysis | 4 | 40.0 |
Neurons/analysis | 3 | 37.0 |
Brain Mapping | 2 | 1.0 |
Receptors, Neurotransmitter/drug effects/*metabolism | 3 | 100.0 |
Nutritional Status | 2 | 1.0 |
Peptide PHI/metabolism | 2 | 50.0 |
Hirschsprung Disease/*metabolism | 2 | 40.0 |
Norepinephrine/*secretion | 2 | 66.0 |
Sympathetic Nervous System/*drug effects | 2 | 13.0 |
Isoelectric Focusing | 2 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Heart/*drug effects | 2 | 5.0 |
Myocardial Contraction/*drug effects | 2 | 8.0 |
Adrenal Gland Neoplasms/*blood | 2 | 100.0 |
Kidney Failure, Chronic/*blood | 2 | 3.0 |
Pheochromocytoma/*blood | 2 | 66.0 |
Endothelins | 2 | 50.0 |
Calcitonin Gene-Related Peptide | 12 | 48.0 |
Endothelium, Vascular/*physiology | 2 | 1.0 |
Muscles/*blood supply | 2 | 25.0 |
Alzheimer Disease/*metabolism/pathology | 3 | 3.0 |
Neurofibrils/pathology | 2 | 16.0 |
Somatostatin/*metabolism | 2 | 8.0 |
Nerve Fibers/analysis | 3 | 42.0 |
Renal Artery/drug effects | 2 | 66.0 |
Choline O-Acetyltransferase/metabolism | 2 | 1.0 |
Sympathetic Nervous System/physiopathology | 2 | 8.0 |
Drinking Behavior/drug effects | 2 | 40.0 |
Cerebral Arteries/*drug effects | 2 | 100.0 |
Atropine/pharmacology | 2 | 5.0 |
Neurons/*analysis | 6 | 54.0 |
Antibodies/immunology | 2 | 0.0 |
Birds | 3 | 10.0 |
Neuropeptide Y/blood/*metabolism | 2 | 100.0 |
Hypothalamus/*analysis | 3 | 50.0 |
Nerve Tissue Proteins/*genetics | 2 | 0.0 |
Immunochemistry | 2 | 0.0 |
Nerve Tissue Proteins/*blood | 3 | 18.0 |
Peptides/analysis/*physiology | 2 | 50.0 |
Nerve Tissue Proteins/*analysis/immunology | 5 | 45.0 |
Neurotensin/metabolism | 2 | 20.0 |
Vas Deferens/drug effects | 2 | 100.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
*Electroacupuncture | 2 | 25.0 |
*Radioimmunoassay | 2 | 5.0 |
Immunosorbent Techniques | 2 | 0.0 |
Pituitary Gland/analysis | 2 | 33.0 |
Taste | 2 | 16.0 |
Neurons/physiology | 2 | 1.0 |
Spin Labels | 2 | 1.0 |
Receptors, Neuropeptide Y/agonists/antagonists & inhibitors | 2 | 100.0 |
